Laddar...
The Use of BDDCS in Classifying the Permeability of Marketed Drugs()
We recommend that regulatory agencies add the extent of drug metabolism (i.e., ≥90% metabolized) as an alternate method in defining Class 1 marketed drugs suitable for a waiver of in vivo studies of bioequivalence. That is, ≥90% metabolized is an additional methodology that may be substituted for ≥9...
Sparad:
| Huvudupphovsmän: | , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2008
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3580995/ https://ncbi.nlm.nih.gov/pubmed/18236138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11095-007-9523-x |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|